3-氯-2-甲氧基吡啶-4-硼酸 | 957060-88-7

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-氯-2-甲氧基吡啶-4-硼酸
• 中文别名: 3-氯-2-甲氧基吡啶-4-硼酸,95；2-甲氧基-3-氯吡啶-4-硼酸；3-氯-2-甲氧基吡啶-4-硼酸,95%
• 英文名称: (3-chloro-2-methoxypyridin-4-yl)boronic acid
• 英文别名: 3-chloro-2-methoxypyridine-4-boronic acid
• CAS: 957060-88-7
• 化学式: C₆H₇BClNO₃
• mdl: MFCD06798255
• 分子量: 187.39
• InChiKey: YQNAXOGPSUVHNU-UHFFFAOYSA-N

物化性质

• 熔点：
  140°C

计算性质

• 辛醇/水分配系数(LogP)：
  1.29
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  62.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-Chloro-2-methoxypyridine-4-boronic acid
Product Name:
Synonyms: 3-Chloro-2-methoxy-4-pyridineboronic acid; 3-Chloro-2-methoxypyridin-4-ylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-Chloro-2-methoxypyridine-4-boronic acid
Ingredient name:
CAS number: 957060-88-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H7BClNO3
Molecular weight: 187.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯-2-甲氧基吡啶-4-硼酸 在 盐酸 、 titanium(IV) tetraethanolate 、 potassium dihydrogenphosphate 、 methanesulfonato(2-dicyclohexylphosphino-2’-6’-di-i-propoxy-1,1‘-biphenyl)(2-amino-1,1‘-biphenyl-2-yl)palladium(II) 、 三氯氧磷 、 2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 13.0h， 生成
  参考文献：
  名称：

  [EN] PYRIDINE OR PYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF
  [FR] DÉRIVÉ DE PYRIDINE OU DE PYRIMIDINE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 吡啶或嘧啶类衍生物及其制备方法和用途

  摘要：

  本发明涉及吡啶或嘧啶类衍生物、其制备方法及其在医药上的应用。具体而言，本发明涉及一种通式（I）所示的吡啶或嘧啶类衍生物、其制备方法及其可药用的盐，以及它们作为治疗剂，特别是SHP2变构抑制剂的用途，其中通式（I）中的各取代基的定义与说明书中的定义相同，

  公开号：

  WO2022007869A1

文献信息

• Alkyl−(Hetero)Aryl Bond Formation via Decarboxylative Cross-Coupling: A Systematic Analysis
  作者：Frederik Sandfort、Matthew J. O'Neill、Josep Cornella、Laurin Wimmer、Phil S. Baran

  DOI：10.1002/anie.201612314

  日期：2017.3.13

  useful surrogates for alkyl halides in cross‐coupling chemistry. Such esters are easily accessible through reactions between ubiquitous carboxylic acids and coupling agents widely used in amide bond formation. This article features an amalgamation of in‐house experience bolstered by approximately 200 systematically designed experiments to accelerate the selection of ideal reaction conditions and activating

  Suzuki，Negishi和Kumada偶联是骨骼C-C键形成过程中最重要的反应。它们广泛地用于在两个芳环之间建立键，这使得化学科学的每个分支都可以使用。由于缺乏可商购的卤化物结构单元，烷基卤化物和金属化的芳基体系之间的类似结合未被广泛采用。氧化还原活性酯最近在交叉偶联化学中作为烷基卤的有用替代物出现。通过普遍存在的羧酸与广泛用于酰胺键形成的偶联剂之间的反应，可以容易地获得这类酯。
• INDOLE DERIVATIVES AS CRAC MODULATORS
  申请人：Alam Muzaffar

  公开号：US20110071150A1

  公开（公告）日：2011-03-24

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 and R 4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

  公式I的化合物： 或其药用可接受的盐， 其中R1、R2、R3和R4按本文定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与钙释放激活钙通道（CRAC）相关疾病的用途。
• Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors
  申请人：Connors Richard V.

  公开号：US20110142796A1

  公开（公告）日：2011-06-16

  Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.

  本发明提供了一种在治疗CDK4介导的疾病（如癌症）中有用的化合物、药物组合物和方法。所述化合物是融合的吡啶、嘧啶和三嗪衍生物。
• 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS
  申请人：Bissantz Caterina

  公开号：US20120232051A1

  公开（公告）日：2012-09-13

  This invention relates to novel 3-aminopyridines of the formula wherein B 1 , B 2 and R 1 to R 6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

  本发明涉及一种新型的3-氨基吡啶，其化学式如下：其中B1、B2和R1至R6在说明书和权利要求书中定义，以及其药学上可接受的盐。这些化合物是GPBAR1激动剂，可用作治疗2型糖尿病等疾病的药物。
• Modulators of CFTR
  申请人：Hadida-Ruah Sara

  公开号：US08969386B2

  公开（公告）日：2015-03-03

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物，可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节因子（“CFTR”）。本发明还涉及使用本发明的化合物治疗CFTR介导疾病的方法。